Cargando…

Poly (ADP-ribose) polymerase 3 (PARP3), a potential repressor of telomerase activity

BACKGROUND: Considering previous result in Non-Small Cell Lung Cancer (NSCLC), we investigated in human cancer cells the role of PARP3 in the regulation of telomerase activity. METHODS: We selected A549 (lung adenocarcinoma cell line) and Saos-2 (osteosarcoma cell line), with high and low telomerase...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernández-Marcelo, Tamara, Frías, Cristina, Pascua, Irene, de Juan, Carmen, Head, Jacqueline, Gómez, Ana, Hernando, Florentino, Jarabo, Jose-Ramon, Díaz-Rubio, Eduardo, Torres, Antonio-Jose, Rouleau, Michèle, Benito, Manuel, Iniesta, Pilar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937032/
https://www.ncbi.nlm.nih.gov/pubmed/24528514
http://dx.doi.org/10.1186/1756-9966-33-19
_version_ 1782305414659964928
author Fernández-Marcelo, Tamara
Frías, Cristina
Pascua, Irene
de Juan, Carmen
Head, Jacqueline
Gómez, Ana
Hernando, Florentino
Jarabo, Jose-Ramon
Díaz-Rubio, Eduardo
Torres, Antonio-Jose
Rouleau, Michèle
Benito, Manuel
Iniesta, Pilar
author_facet Fernández-Marcelo, Tamara
Frías, Cristina
Pascua, Irene
de Juan, Carmen
Head, Jacqueline
Gómez, Ana
Hernando, Florentino
Jarabo, Jose-Ramon
Díaz-Rubio, Eduardo
Torres, Antonio-Jose
Rouleau, Michèle
Benito, Manuel
Iniesta, Pilar
author_sort Fernández-Marcelo, Tamara
collection PubMed
description BACKGROUND: Considering previous result in Non-Small Cell Lung Cancer (NSCLC), we investigated in human cancer cells the role of PARP3 in the regulation of telomerase activity. METHODS: We selected A549 (lung adenocarcinoma cell line) and Saos-2 (osteosarcoma cell line), with high and low telomerase activity levels, respectively. The first one was transfected using a plasmid construction containing a PARP3 sequence, whereas the Saos-2 cells were submitted to shRNA transfection to get PARP3 depletion. PARP3 expression on both cell systems was evaluated by real-time quantitative PCR and PARP3 protein levels, by Western-blot. Telomerase activity was determined by TRAP assay. RESULTS: In A549 cells, after PARP3 transient transfection, data obtained indicated that twenty-four hours after transfection, up to 100-fold increased gene expression levels were found in the transfected cells with pcDNA/GW-53/PARP3 in comparison to transfected cells with the empty vector. Moreover, 48 hours post-transfection, telomerase activity decreased around 33%, and around 27%, 96 hours post-transfection. Telomerase activity average ratio was 0.67 ± 0.05, and 0.73 ± 0.06, respectively, with significant differences. In Saos-2 cells, after shRNA-mediated PARP3 silencing, a 2.3-fold increase in telomerase activity was detected in relation to the control. CONCLUSION: Our data indicated that, at least in some cancer cells, repression of PARP3 could be responsible for an increased telomerase activity, this fact contributing to telomere maintenance and, therefore, avoiding genome instability.
format Online
Article
Text
id pubmed-3937032
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39370322014-02-28 Poly (ADP-ribose) polymerase 3 (PARP3), a potential repressor of telomerase activity Fernández-Marcelo, Tamara Frías, Cristina Pascua, Irene de Juan, Carmen Head, Jacqueline Gómez, Ana Hernando, Florentino Jarabo, Jose-Ramon Díaz-Rubio, Eduardo Torres, Antonio-Jose Rouleau, Michèle Benito, Manuel Iniesta, Pilar J Exp Clin Cancer Res Research BACKGROUND: Considering previous result in Non-Small Cell Lung Cancer (NSCLC), we investigated in human cancer cells the role of PARP3 in the regulation of telomerase activity. METHODS: We selected A549 (lung adenocarcinoma cell line) and Saos-2 (osteosarcoma cell line), with high and low telomerase activity levels, respectively. The first one was transfected using a plasmid construction containing a PARP3 sequence, whereas the Saos-2 cells were submitted to shRNA transfection to get PARP3 depletion. PARP3 expression on both cell systems was evaluated by real-time quantitative PCR and PARP3 protein levels, by Western-blot. Telomerase activity was determined by TRAP assay. RESULTS: In A549 cells, after PARP3 transient transfection, data obtained indicated that twenty-four hours after transfection, up to 100-fold increased gene expression levels were found in the transfected cells with pcDNA/GW-53/PARP3 in comparison to transfected cells with the empty vector. Moreover, 48 hours post-transfection, telomerase activity decreased around 33%, and around 27%, 96 hours post-transfection. Telomerase activity average ratio was 0.67 ± 0.05, and 0.73 ± 0.06, respectively, with significant differences. In Saos-2 cells, after shRNA-mediated PARP3 silencing, a 2.3-fold increase in telomerase activity was detected in relation to the control. CONCLUSION: Our data indicated that, at least in some cancer cells, repression of PARP3 could be responsible for an increased telomerase activity, this fact contributing to telomere maintenance and, therefore, avoiding genome instability. BioMed Central 2014-02-15 /pmc/articles/PMC3937032/ /pubmed/24528514 http://dx.doi.org/10.1186/1756-9966-33-19 Text en Copyright © 2014 Fernández-Marcelo et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Fernández-Marcelo, Tamara
Frías, Cristina
Pascua, Irene
de Juan, Carmen
Head, Jacqueline
Gómez, Ana
Hernando, Florentino
Jarabo, Jose-Ramon
Díaz-Rubio, Eduardo
Torres, Antonio-Jose
Rouleau, Michèle
Benito, Manuel
Iniesta, Pilar
Poly (ADP-ribose) polymerase 3 (PARP3), a potential repressor of telomerase activity
title Poly (ADP-ribose) polymerase 3 (PARP3), a potential repressor of telomerase activity
title_full Poly (ADP-ribose) polymerase 3 (PARP3), a potential repressor of telomerase activity
title_fullStr Poly (ADP-ribose) polymerase 3 (PARP3), a potential repressor of telomerase activity
title_full_unstemmed Poly (ADP-ribose) polymerase 3 (PARP3), a potential repressor of telomerase activity
title_short Poly (ADP-ribose) polymerase 3 (PARP3), a potential repressor of telomerase activity
title_sort poly (adp-ribose) polymerase 3 (parp3), a potential repressor of telomerase activity
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937032/
https://www.ncbi.nlm.nih.gov/pubmed/24528514
http://dx.doi.org/10.1186/1756-9966-33-19
work_keys_str_mv AT fernandezmarcelotamara polyadpribosepolymerase3parp3apotentialrepressoroftelomeraseactivity
AT friascristina polyadpribosepolymerase3parp3apotentialrepressoroftelomeraseactivity
AT pascuairene polyadpribosepolymerase3parp3apotentialrepressoroftelomeraseactivity
AT dejuancarmen polyadpribosepolymerase3parp3apotentialrepressoroftelomeraseactivity
AT headjacqueline polyadpribosepolymerase3parp3apotentialrepressoroftelomeraseactivity
AT gomezana polyadpribosepolymerase3parp3apotentialrepressoroftelomeraseactivity
AT hernandoflorentino polyadpribosepolymerase3parp3apotentialrepressoroftelomeraseactivity
AT jarabojoseramon polyadpribosepolymerase3parp3apotentialrepressoroftelomeraseactivity
AT diazrubioeduardo polyadpribosepolymerase3parp3apotentialrepressoroftelomeraseactivity
AT torresantoniojose polyadpribosepolymerase3parp3apotentialrepressoroftelomeraseactivity
AT rouleaumichele polyadpribosepolymerase3parp3apotentialrepressoroftelomeraseactivity
AT benitomanuel polyadpribosepolymerase3parp3apotentialrepressoroftelomeraseactivity
AT iniestapilar polyadpribosepolymerase3parp3apotentialrepressoroftelomeraseactivity